Literature DB >> 11719328

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection.

A Greenough1, S Cox, J Alexander, W Lenney, F Turnbull, S Burgess, P A Chetcuti, N J Shaw, A Woods, J Boorman, S Coles, J Turner.   

Abstract

AIMS: To compare the use of health care resources and associated costs between infants with chronic lung disease (CLD) who had or had not an admission with a proven respiratory syncytial virus (RSV) infection.
METHODS: Review of community care, outpatient attendances, and readmissions in the first two years after birth. PATIENTS: 235 infants (median gestational age 27 weeks) evaluated in four groups: 45 infants with a proven RSV admission (RSV proven); 24 with a probable bronchiolitis admission; 60 with other respiratory admissions; and 106 with non-respiratory or no admissions.
RESULTS: The RSV proven compared to the other groups required more frequent and longer admissions to general paediatric wards and intensive care units, more outpatient attendances and GP consultations for respiratory related disorders, and had a higher total cost of care.
CONCLUSION: RSV hospitalisation in patients with CLD is associated with increased health service utilisation and costs in the first two years after birth.

Entities:  

Mesh:

Year:  2001        PMID: 11719328      PMCID: PMC1719001          DOI: 10.1136/adc.85.6.463

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

Review 1.  Advances in prevention of respiratory syncytial virus infections.

Authors:  C G Prober; W M Sullender
Journal:  J Pediatr       Date:  1999-11       Impact factor: 4.406

2.  Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort.

Authors:  S J Clark; M W Beresford; N V Subhedar; N J Shaw
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

3.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

Authors:  N Sigurs; R Bjarnason; F Sigurbergsson; B Kjellman
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Rehospitalization for respiratory syncytial virus among premature infants.

Authors:  S Joffe; G J Escobar; S B Black; M A Armstrong; T A Lieu
Journal:  Pediatrics       Date:  1999-10       Impact factor: 7.124

5.  Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.

Authors:  M Thomas; A Bedford-Russell; M Sharland
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

6.  Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.

Authors:  A Marchetti; H Lau; R Magar; L Wang; G Devercelli
Journal:  Clin Ther       Date:  1999-04       Impact factor: 3.393

7.  Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.

Authors:  T G Boyce; B G Mellen; E F Mitchel; P F Wright; M R Griffin
Journal:  J Pediatr       Date:  2000-12       Impact factor: 4.406

8.  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years.

Authors:  R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

9.  Chronic respiratory morbidity following premature delivery--prediction by prolonged respiratory support requirement?

Authors:  M Kinali; A Greenough; G Dimitriou; B Yüksel; R Hooper
Journal:  Eur J Pediatr       Date:  1999-06       Impact factor: 3.183

Review 10.  Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.

Authors:  R C Welliver
Journal:  Semin Perinatol       Date:  1998-02       Impact factor: 3.300

View more
  57 in total

1.  Post-natal corticosteroid use.

Authors:  Olivia Williams; Anne Greenough
Journal:  Eur J Pediatr       Date:  2003-07-16       Impact factor: 3.183

2.  Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness.

Authors:  Cameron F Gunville; Marci K Sontag; Kristin A Stratton; Daksha J Ranade; Steven H Abman; Peter M Mourani
Journal:  J Pediatr       Date:  2010-03-24       Impact factor: 4.406

3.  Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Authors:  T Heikkinen; H Valkonen; L Lehtonen; R Vainionpää; O Ruuskanen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-01       Impact factor: 5.747

4.  Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany.

Authors:  Birgit Ehlken; Gabriele Ihorst; Barbara Lippert; Angela Rohwedder; Gudula Petersen; Martin Schumacher; Johannes Forster
Journal:  Eur J Pediatr       Date:  2005-06-18       Impact factor: 3.183

5.  RSV and bronchiolitis.

Authors:  H L A Van Rostenberghe; S T Kew; M J M Hanifah
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-03       Impact factor: 5.747

6.  Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease.

Authors:  A Greenough; J Alexander; S Burgess; P A J Chetcuti; S Cox; W Lenney; F Turnbull; N J Shaw; A Woods; J Boorman; S Coles; J Turner
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

7.  Respiratory morbidity, healthcare utilisation and cost of care at school age related to home oxygen status.

Authors:  Anne Greenough; John Alexander; Jill Boorman; Philip A J Chetcuti; Ian Cliff; Warren Lenney; Colin Morgan; Nigel J Shaw; Karl P Sylvester; Jackie Turner
Journal:  Eur J Pediatr       Date:  2011-01-12       Impact factor: 3.183

Review 8.  How has research in the past 5 years changed my clinical practice.

Authors:  Anne Greenough
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

9.  Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

Authors:  Joseph M Geskey; Neal J Thomas; Gretchen L Brummel
Journal:  Biologics       Date:  2007-03

10.  Compliance with RSV prophylaxis: Global physicians' perspectives.

Authors:  Kari S Anderson; Victoria M Mullally; Linda M Fredrick; Andrew L Campbell
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.